Biocon: Biocon Biologics, a subsidiary of Biocon, reported encouraging findings from Phase III clinical trials for its ...

Piramal Pharma has set an ambitious target to double its revenue to $2 billion by FY30, while also tripling its Ebitda, ...

Under the terms of this agreement, Biocon will develop and manufacture the products, and Tabuk Pharmaceuticals will hold the ...

The global psoriatic arthritis (PsA) treatment market is poised for remarkable expansion, with an anticipated valuation of ...

Piramal Pharma aims to double its revenue to $2 billion by FY30, while tripling its Ebitda, said company Chairperson Nandini ...

Two Phase 3 studies have demonstrated that patients can safely switch between adalimumab, a well-known biologic therapy, and ...

Sensex ended the day with the gain of 256 points to 85,169 and Nifty surged 63 points to 26,004 on. Nifty Bank zoomed 133 ...

Biocon Biologics presents new dermatology data from two clinical studies at EADV Congress 2024: Our Bureau, Bengaluru Wednesday, September 25, 2024, 13:40 Hrs [IST] Biocon Biologi ...

Mumbai-based alternative investment firm True North, which runs private equity and credit funds and has backed names like ...

Biocon Biologics presents dermatology data at EADV 2024 Congress, showcasing interchangeability and biosimilarity of ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced new dermatology data ...

A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar ...